echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Takeda failed to overturn the $9 billion penalty for concealing the risk of pioglitazone

    Takeda failed to overturn the $9 billion penalty for concealing the risk of pioglitazone

    • Last Update: 2014-09-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Ding Xiangyuan 2014-9-1 according to the court's ruling, Takeda pharmaceutical and Lilly failed to overturn the US jury's US $9 billion punitive damages for concealing the cancer risk associated with the diabetes drug pioglitazone "The prosecutor has pointed out sufficient evidence from which the jury may conclude that the bladder cancer 'information' contained in the pioglitazone label does not adequately warn of the increased cancer risk of the drug," said Doherty, a U.S district judge in Western Louisiana The development is a setback for Takeda, but it still leaves the door open to review or reduce the possibility of the award of compensation, for which Japan's largest pharmaceutical company held a separate appeal in April A spokesman called the latest ruling "unfortunate" and added that Takeda still wanted a result that supported a separate appeal Takeda reiterated his intention to continue to fight, rather than solve the problem in court Legal experts say it is impossible for such a huge decision to be overturned in court by the two companies Lilly, which co sold pioglitazone from 1999 to 2006, did not immediately comment on the ruling Lilly had previously said that under the terms of its contract with Takeda, the company would be exempt from Takeda's compensation for losses and expenses incurred in legal proceedings Pioglitazone is an oral type 2 diabetes drug that regulates blood glucose levels and has been approved for marketing since 1999 Takeda recently independently announced a 10-year epidemiological study that found no evidence that pioglitazone increased the risk of bladder cancer Takeda said the data had been submitted to regulators in the United States, Europe and Japan This is the first case to be tried that has been sorted out and prosecuted in multiple regions It contains more than 2900 legal proceedings In all three previous pioglitazone trials, Takeda said the verdict was in its favor Original address: http://
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.